The US FDA has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

The US FDA has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).
The US FDA has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD). submitted by /u/mvea
[link] [comments]
https://ift.tt/2shy8zr November 25, 2019 at 04:49PM https://ift.tt/1R552o9
by at
Tags

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)